Last reviewed · How we verify
ONO-2333Ms Experimental 1 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
ONO-2333Ms Experimental 1 (ONO-2333Ms Experimental 1) — Ono Pharma USA Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ONO-2333Ms Experimental 1 TARGET | ONO-2333Ms Experimental 1 | Ono Pharma USA Inc | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ONO-2333Ms Experimental 1 CI watch — RSS
- ONO-2333Ms Experimental 1 CI watch — Atom
- ONO-2333Ms Experimental 1 CI watch — JSON
- ONO-2333Ms Experimental 1 alone — RSS
Cite this brief
Drug Landscape (2026). ONO-2333Ms Experimental 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/ono-2333ms-experimental-1. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing